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Background: It is not known whether children with acute promyelocytic leukemia (APL) have an infection risk
similar to non- APL acute myeloid leukemia. The objective was to describe infectious risk in children with newly
diagnosed APL and to describe factors associated with these infections.
Methods: We conducted a retrospective, population-based cohort study that included children≤ 18 years of age
with de novo APL treated at 15 Canadian centers. Thirty-three children with APL were included; 78.8% were treated
with APL -specific protocols.
Results: Bacterial sterile site infection occurred in 12 (36.4%) and fungal sterile site infection occurred in 2 (6.1%)
children. Of the 127 chemotherapy courses, 101 (79.5%) were classified as intensive and among these, the
proportion in which a sterile site microbiologically documented infection occurred was 14/101 (13.9%). There was
one infection-related death.
Conclusions: One third of children with APL experienced at least one sterile site bacterial infection throughout
treatment and 14% of intensive chemotherapy courses were associated with a microbiologically documented sterile
site infection. Infection rates in pediatric APL may be lower compared to non- APL acute myeloid leukemia
although these children may still benefit from aggressive supportive care during intensive chemotherapy.
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Children with acute myeloid leukemia (AML) are at sub-
stantial risk of morbidity and mortality from invasive
bacterial and fungal infections [1]. Even with this large
infectious burden, there is great variability in supportive
care strategies used for pediatric AML across institu-
tions [2]. Clinical trials are currently being conducted to
address these uncertainties [3,4]. However, there are
some common themes; most North American centers
do not use routine anti-bacterial prophylaxis (other than* Correspondence: lillian.sung@sickkids.ca
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reproduction in any medium, provided the orfor Pneumocystis jirovecii) and most use fluconazole as
antifungal prophylaxis [2].
Acute promyelocytic leukemia (APL) is a rare sub-type
of AML, comprising only 5-10% of pediatric AML [5].
These children can have a specific and life-threatening
clinical presentation consisting of hemorrhage and
thrombosis, resulting in a relatively high induction death
rate [6]. They also uniquely experience differentiating
syndrome following exposure to all-trans-retinoic acid.
Children with APL are typically excluded from AML
supportive care clinical trials. It is unknown whether
supportive care designed for non-APL AML patients
should be applied to children with APL. We chose to de-
scribe and evaluate infectious toxicities in children with
APL so as to understand whether they are similar to
those in children with other pediatric AML.td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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these children are often very ill at presentation, there are
much less data available on infections in APL derived
from therapeutic clinical trials compared with non-APL
AML clinical trials. Consequently, we conducted a
population-based retrospective study in order to de-
scribe the risk of infection in these children. The pri-
mary objective was to describe infectious risk in children
with newly diagnosed APL and to determine factors as-
sociated with infections in this population.
Methods
This was a retrospective, population-based cohort study
that included children with newly diagnosed APL treated
at all 15 Canadian centers that care for children with
cancer in each province except for Saskatchewan. This
manuscript is related to a larger study in which children
with newly diagnosed non-APL AML in Canada were
examined [7].
Study sample
We included children and adolescents diagnosed with
de novo APL between January 1, 1995 and December
31, 2004 who were age ≤ 18 years at diagnosis and
who received any treatment for APL. We excluded
those with secondary APL and previous diagnosis of
immunodeficiency.
Outcome measures
Infections were examined from initiation of APL treat-
ment until hematopoietic recovery from the last cycle of
chemotherapy, conditioning for hematopoietic stem cell
transplantation, relapse, persistent disease leading to a
change in protocol therapy, or death (whichever oc-
curred first). We used consistent trained clinical re-
search associates to abstract and code the relevant
information.
The rates of sterile site microbiologically documented
infection [8], clinically documented infection and fever
of unknown origin were expressed as the number of
events during the time period at risk. Positive cultures
with common contaminants such as coagulase negative
Staphylococcus were only considered true infection if
there were two or more positive cultures within the
same episode or if the infection was associated with sep-
sis [9,10]. A patient was considered to have sepsis if
there was systemic inflammatory response syndrome in
the presence of suspected or proven infection and organ
dysfunction according to international consensus guide-
lines [11,12]. Classification of clinically documented in-
fections was based upon the Centers for Disease Control
and Prevention definitions of nosocomial infections [13].
Fever of unknown origin was defined as a fever occur-
ring in the absence of a positive microbiology result orclinical site of infection. Infections were evaluated
separately among intensive and non-intensive courses.
Induction and consolidation chemotherapy were consid-
ered intensive. Maintenance chemotherapy was consid-
ered non-intensive and the entire maintenance period
was considered one treatment course as we were
most interested in intensive treatment in terms of infec-
tion outcomes.
Potential predictors
We chose to evaluate factors potentially associated with
infection outcomes only among intensive chemotherapy
courses as these are the most clinically relevant from an
infection supportive care perspective. The following vari-
ables were evaluated: (1) Child characteristics at diagno-
sis (age and obese versus non-obese); (2) Treatment
characteristics (APL-specific treatment protocol, regis-
tration on APL trial, diagnosis prior to January 1, 2000,
and cumulative dose of cytarabine in grams/m2); (3)
Course characteristics (neutropenia at the start of the
course, neutropenia >15 days (threshold chosen a
priori), and days systemic corticosteroids were adminis-
tered for any reason).
Obesity was defined as a body mass index ≥ 95 per-
centile for age and gender according to the Centers for
Disease Control and Prevention for those at least 2 years
of age [14].
Statistics
Regression analyses were conducted at the course level
and only included intensive chemotherapy. Factors asso-
ciated with rates of microbiologically documented sterile
site infection, clinically documented infection and fever
of unknown origin were examined using repeated mea-
sures Poisson regression and the association was
expressed as a rate ratio (RR) with 95% confidence inter-
val (CI). Multiple regression was conducted using vari-
ables significant in univariate analysis. In order to
evaluate co-linearity and which variables should not be
concurrently included in the multiple regression model,
Spearman correlation coefficients (r) were examined. All
tests of significance were two-sided, and statistical sig-
nificance was defined as P <0.05. Statistical analysis was
performed using the SAS statistical program (SAS-PC,
version 9.3; SAS Institute Inc., Cary, NC).
Ethical approvals
This study was approved by the Research Ethics Board
at The Hospital for Sick Children and local Research
Ethics Boards of the 14 other participating sites
(McMaster University-Hamilton Health Sciences/Faculty
of Health Sciences Research Ethics Board, Montreal
Children’s Hospital Research Ethics Board, Children’s
Hospital of Eastern Ontario Research Ethics Board,
Table 1 Demographic and treatment characteristics for
children with acute promyelocytic leukemia (N = 33)
Value
Child characteristics at diagnosis
Male (%) 16 (48.5)
Median age in years (IQR) 12.5 (7.2, 15.6)
Down syndrome (%) 1 (3.0)
Body mass index (%), N = 321
Obese 10 (31.2)
Normal weight 22 (68.8)
Median white blood cell count at diagnosis
(×109/L) (IQR)
4.8 (2.5, 15.0)









Non-APL specific AML protocol 7 (21.2)
Registered on study (%) 4 (12.1)
Abbreviations: IQR interquartile range, APL acute promyelocytic leukemia, AML
acute myeloid leukemia; 1 One patient < 2 years of age at diagnosis; 2 ANC
unavailable for two patients at diagnosis; 3 Includes APL standard of care (n = 1),
Children’s Cancer Group 2911 (n = 5), Children’s Oncology Group A9710 (n = 20).
Table 2 Course characteristics and infection outcomes (N = 12
All (N = 1
Course characteristics
Number with neutropenia (ANC <0.5 × 109) at start of course (%) 27 (21.3
Median days with neutropenia1(IQR) 7.5 (0.0, 1
Median days receiving systemic corticosteroids (IQR) 0.0 (0.0, 5
Median corticosteroid dose1 (IQR) 0.0 (0.0, 2
Supportive care
Co-trimoxazole prophylaxis (%) 89 (70.1
Other antibacterial prophylaxis (%) 0
Fluconazole prophylaxis (%) 30 (23.6
Infection outcomes2
Sterile site microbiologically documented infection (%) 15 (11.8
Sterile site Gram-positive (%) 12 (9.5
Sterile site Gram-negative (%) 4 (3.2)
Sterile site fungus (%) 2 (1.6)
Bacteremia (%) 11 (8.7
Clinically documented infection (%) 30 (23.6
Sepsis 8 (6.3)
Infectious death 1 (0.8)
Abbreviations: ANC absolute neutrophil count, IQR interquartile range; 1 Presented a
least one event per course; number of specific infections do not add to the total as
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of British Columbia/Children’s and Women’s Health
Centre of British Columbia Research Ethics Board, Centre
Hospitalier Universitaire Sainte-Justine Research Ethics
Board, University of Calgary Conjoint Health Research
Ethics Board, IWK Research Ethics Board, Queen’s
University-Health Sciences Research Ethics Board, Uni-
versity of Western Ontario Research Ethics Board for
Health Science Research Involving Human Subjects,
Memorial University Human Investigation Committee,
Centre Hospitalier Universitaire de Quebec Research
Ethics Board, University of Alberta Health Research
Ethics Board-Biomedical Panel, Centre Hospitalier
Universitaire de Sherbrooke Research Ethics Board). As
this was a retrospective review study the Research Eth-
ics Board at The Hospital for Sick Children and those at
the 14 other participating sites waived the need for writ-
ten informed consent.
Results
In terms of demographics, of the 33 children with APL
included in this analysis, most (78.8%) were treated
according to APL-specific protocols (Table 1). The me-
dian days receiving intensive chemotherapy (from first
to last administration) was 79 days (interquartile range
(IQR) 67 to 104 days) and the median days receiving
maintenance chemotherapy was 396 days (IQR 135 to
565 days). Among the 33 children, throughout the7)
27) Intensive treatment (N = 101) APL-specific treatment (N = 99)
) 27 (26.7) 21 (21.2)
9.0) 11.0 (0.0, 20.0) 3.0 (0.0, 18.0)
.0) 0.0 (0.0, 6.0) 0.0 (0.0, 3.0)
9.7) 0.0 (0.0, 38.4) 0.0 (0.0, 5.7)
) 71 (70.3) 77 (77.8)
0 0
) 27 (26.7) 18 (18.2)
) 14 (13.9) 9 (9.1)
) 11 (10.9) 7 (7.1)
4 (4.0) 2 (2.0)
2 (2.0) 2 (2.0)
) 10 (9.9) 7 (7.1)
) 24 (23.8) 26 (26.3)
7 (6.9) 8 (8.1)
1 (1.0) 1 (1.0)
s mg/m2 of dexamethasone equivalents; 2Infection outcomes represent at
3 courses had multiple infection types.
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sterile site infection and 2 (6.1%) experienced any fungal
sterile site infection (both candidemia).
Table 2 illustrates the course characteristics and support-
ive care received among all 127 courses; 101 were classified
as intensive (79.5%) and 99 were classified as APL specific
(78.0%). Among intensive treatment courses, the propor-
tion in which a sterile site microbiologically documented
infection occurred was 14/101 (13.9%) while the number
in which a sterile site fungal infection occurred was 2/101
(2.0%). The table also illustrates that there were 8 courses
complicated by sepsis and 1 infection-related death due to
Klebsiella pneumoniae bacteremia.
Treatment with an APL-specific protocol was not as-
sociated with significantly fewer microbiologically docu-
mented sterile site infections when only intensive
treatment courses were included (Table 3). Only treat-
ment in an earlier era, and a higher cytarabine dose were
associated with higher rates of infection. Neutropenia at
the start of the course and prolonged neutropenia were
both significantly associated with clinically documented
infection (Table 3). Finally, the only factors associatedTable 3 Predictors of the rates of microbiologically document
and fever of unknown origin per course among intensive trea
Microbiological sterile
Rate ratio P v
(CI)
Child characteristics at diagnosis
Age in years 0.92 0.0
(0.84, 1.01)
Obese vs. non-obese1 0.92 0.8
(0.29, 2.93)
Treatment characteristics
APL-specific treatment protocol 0.77 0.6
(0.25, 2.37)
Registered on study 1.91 0.1
(0.77, 4.70)
Diagnosed prior to January 1, 2000 3.18 0.0
(1.12, 9.04)
Cumulative dose of cytarabine (g/m2) 1.09 0.0
(1.02, 1.16)
Course characteristics
Neutropenia (ANC <0.5 ×109) at start of course 0.99 0.9
(0.32, 3.06)
Greater than 15 days with neutropenia 2.04 0.2
(0.67, 6.21)
Days receiving corticosteroids 1.04 0.0
(1.00, 1.09)
Abbreviations: APL acute promyelocytic leukemia, ANC absolute neutrophil count, Cwith more fever of unknown origin were younger age
and diagnosis in an earlier era.
When evaluating course characteristics, diagnosis
prior to January 1, 2000 was correlated with cumulative
cytarabine dose (Spearman r = 0.385, P < 0.0001) and
thus, multiple regression was not conducted for micro-
biologically documented sterile site infection. Similarly,
neutropenia at the start of the course was correlated
with prolonged duration of neutropenia (Spearman r =
0.469, P < 0.0001) and thus, multiple regression was also
not conducted for clinically documented infection. Age
(RR 0.93, 95% CI 0.87 to 0.99; P = 0.033) and diagnosis
in an earlier era (RR 2.53, 95% CI 1.17 to 5.46; P = 0.019)
were both independently associated with fever of un-
known origin.
Of the specific infections documented, Gram-positive
bacterial infections were more common than Gram-
negative or fungal infections (Table 4). Among the 3
fungal infections, 2 were from a sterile site (both Can-
dida albicans) while 1 was from a non-sterile site
(Alternaria species). Only the patient with Alternaria in-
fection received antifungal prophylaxis with fluconazole.ed sterile site infection clinically documented infection
tment courses (N = 101)
site Clinically documented Fever of unknown origin
alue Rate ratio P value Rate ratio P value
(CI) (CI)
82 0.99 0.748 0.92 0.025
(0.92, 1.06) (0.85, 0.99)
91 0.60 0.268 0.40 0.103
(0.24, 1.48) (0.13, 1.20)
43 2.63 0.127 0.69 0.496
(0.76, 9.10) (0.24, 2.01)
62 1.24 0.553 0.49 0.385
(0.62, 2.48) (0.10, 2.43)
30 1.22 0.691 2.87 0.018
(0.46, 3.18) (1.20, 6.86)
08 0.97 0.522 0.99 0.763
(0.88, 1.07) (0.90, 1.08)
90 5.68 <0.0001 1.36 0.436
(2.42, 13.31) (0.63, 2.93)
08 4.18 0.001 2.01 0.138
(1.81, 9.62) (0.80, 5.07)
64 1.03 0.075 1.01 0.555
(1.00, 1.07) (0.97, 1.05)
I confidence interval; 1 Obesity only available for children ≥ 2 years of age.
Table 4 Microbiologically documented infections
observed during therapy (N = 29)
Organism n (%)
Sterile site bacteria*
Gram positive 13 (44.8)
Viridans group streptococci 6 (20.7)
Coagulase negative staphylococci 5 (17.2)
Enterococcus faecalis 1 (3.4)
Mycoplasma pneumoniae 1 (3.4)
Gram Negative 4 (13.8)
Escherichia coli 2 (7.0)
Klebsiella pneumoniae 1 (3.4)
Enterobacter cloacae 1 (3.4)
Fungus* 3 (10.3)
Candida albicans 2 (7.0)
Alternaria NOS 1 (3.4)
Virus* 9 (31.0)
Herpes simplex virus 2 (7.0)
Respiratory syncytial virus 1 (3.4)
Torovirus 4 (13.8)
Other1 2 (7.0)
Abbreviation: NOS not otherwise specified;
* For bacterial infections, only sterile site positive cultures are shown. For fungi
and viruses, both sterile and non-sterile site positive cultures are shown;
1 Others were adenovirus (n = 1) and influenza A (n = 1).
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We found that among children with APL, one third ex-
perienced at least one sterile site bacterial infection
throughout treatment and 14% of intensive chemother-
apy courses were associated with a microbiologically
documented sterile site infection. Invasive fungal infec-
tion was rare but did occur. Further, we found that the
risk of infection has decreased over time.
These infection rates appear lower than those de-
scribed for pediatric non-APL AML treatment protocols.
In an evaluation of children enrolled on the Children’s
Cancer Group 2961 protocol, more than 60% of children
experienced a microbiologically documented infection
during each course of therapy [15]. In an analysis of
AAML0531, the most recently completed Children’s On-
cology Group phase 3 AML trial, over 80% of children
experienced at least one sterile site bacterial infection
while 14% experienced at least one sterile site fungal in-
fection throughout chemotherapy. The risk of sterile site
bacterial infection was 30 to 60% per course [16].
Within our Canadian study focused on infections in
AML, the cumulative risk of bacteremia was 54.3% for
children with non-APL AML [7], compared with a
36.4% for any sterile site bacterial infection in this APL-
specific study [7]. When comparing the risk by course,
the risk of sterile site microbiologically documentedinfection was 24.5% in non-APL AML in comparison to
13.9% among intensively treated courses in APL [7].
When put together, these data suggest that the overall
risk of invasive infections among children with APL may
be less than that experienced by children with non-APL
AML. Nonetheless, many children experienced invasive
infections and there were two episodes of candidemia
and one infection-related death. Furthermore, we did not
find that APL-specific treatment protocol was associated
with significantly fewer sterile site microbiologically
documented infection in regression analysis although
power was limited. Consequently, children with APL
may benefit from aggressive supportive care similar to
children with non-APL AML, at least during intensive
courses of chemotherapy.
The rates of infection and infectious deaths have been
variable on adult-predominated APL clinical trials
[17-19]. However, almost none of these studies focused
on infection outcomes. Girmenia et al [20]. evaluated 89
adult and pediatric patients with APL treated with the
AIDA (all-trans retinoic acid plus idarubicin) protocol.
Microbiologically documented infection occurred in
37.4% of patients. Fungal infections were rare. They
compared bloodstream infections in APL patients with
other AML patients and concluded that the incidence of
total septicemia, fungemia and coagulase-negative
staphylococci were significantly lower in APL. One
infection-related death was observed. Consequently, our
results are similar to this study.
In our study of pediatric non-APL AML patients, we
found that exposure to corticosteroids was the most
important factor associated with infection outcomes [7].
In contrast, within this analysis, we found that the asso-
ciation between duration of corticosteroids and rate
of microbiologically documented infection was not sta-
tistically significant (rate ratio 1.04, 95% confidence
interval 1.00 to 1.09; P = 0.064). However, given the ob-
served lower confidence interval of 1.00, it is possible
that this analysis was underpowered to demonstrate an
association.
In this study, 6% of courses were complicated by sep-
sis. It is difficult to know how many courses were, in
fact, truly complicated by infection-related sepsis since
sepsis and differentiation syndrome associated with all-
trans-retinoic acid have many similar features. Jeddi
and colleagues recently highlighted how differentiation
syndrome, which is thought to be mediated through in-
flammatory cytokines generated by APL cells, may not
be distinguishable from sepsis [21]. Nonetheless, our re-
port does provide reassuring data since we have likely
over-estimated the rate of sepsis and the true rate may
be lower.
The strength of our report is that we conducted a
population-based analysis of a very rare sub-type of
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very accurately because of the use of consistent and
specifically trained personnel. The inclusion of very ill
patients at presentation is another important strength of
this study. However, our report must be interpreted in
light of its limitations. APL treatments were heteroge-
neous. Second, supportive care strategies were also vari-
able between centers. Finally, the sample size was small
and many analyses were performed; consequently the re-
sults should be considered hypothesis generating rather
than definitive.
Conclusions
In summary, one third of children with APL experienced
at least one sterile site bacterial infection throughout
treatment and 14% of intensive chemotherapy courses
were associated with a microbiologically documented
sterile site infection. Infection rates in pediatric APL
may be lower compared to non-APL AML although
these children may still benefit from aggressive support-
ive care during intensive chemotherapy. Aggressive sup-
port care could include mandatory hospitalization
during neutropenia and prophylactic antibacterial and
antifungal strategies.
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